Sydney, Australia 13 September 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce favourable imaging data from the Phase II diagnostic investigator-initiated trial (IIT) of 64Cu SAR-Bombesin in prostate cancer,…
Sydney, Australia 25 August 2023 Highlights First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight. Cohort 3 was successfully completed in 3 participants with neuroblastoma who received therapy with 67Cu SARTATE at a dose of 275MBq/kg body…
Sydney, Australia 25 August 2023 First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq. Cohort 2 was recently completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq. Data…
Sydney, Australia 10 August 2023 Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq. No dose limiting toxicities (DLTs) have been reported in cohort 2. The Safety Review Committee…
Sydney, Australia 7 August 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce an exclusive license from Memorial Sloan Kettering Cancer Center (MSK). The license is to intellectual property that…
Sydney, Australia 26 July 2023 Highlights Cohort 3 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE at a dose of 275MBq/kg body weight. Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned. Recruitment of cohort 4 is open at clinical sites in the US at…
Sydney, Australia 24 July 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the Phase II US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with prostate cancer has reached its…
Sydney, Australia 17 July 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, has been awarded First Place in the Oncology, Clinical Therapy & Diagnosis category at the world’s most prestigious nuclear medicine conference,…
Sydney, Australia 4 July 2023 Highlights FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in prostate cancer Phase III trial design based on 64Cu SAR-bisPSMA data package, including positive results from the completed PROPELLER trial A total of 383 prostate cancer patients to take part in a pivotal, non-randomised, single-arm, open-label,…
Sydney, Australia 28 June 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the establishment of a Center of Excellence at the Idaho Accelerator Center (IAC), a research facility operated by Idaho State…